Michael Fisher
Plus aucun poste en cours
Profil
Michael Fisher is Vice President of Operations and Engineering for Xcellerex, Inc. Prior to joining Xcellerex, he was Director of Automation and Systems Validation for Millennium Pharmaceuticals, Inc. from 2001 to 2003, Principal of Private Consulting Group from 1999 to 2001, Director of Manufacturing Operations for AutoImmune, Inc. from 1998 to 1999, Validation Manager of Alpha Beta Technology from 1996 to 1998, Senior Validation Engineer of BASF Biochemical Corp.
from 1993 to 1996, Project Engineer of Burroughs Wellcome from 1991 to 1993, Manufacturing Manager of Life Technologies from 1989 to 1991 and Manufacturing Engineer of MedChem Products from 1985 to 1989.
Mr. Fisher received a BS degree in Chemical Engineering from the University of Massachusetts Amherst (UMass).
Anciens postes connus de Michael Fisher
| Sociétés | Poste | Fin |
|---|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2003 |
AutoImmune, Inc.
 AutoImmune, Inc. Pharmaceuticals: MajorHealth Technology AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA. | Corporate Officer/Principal | 01/01/1999 |
Alpha-Beta Technology, Inc.
 Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Corporate Officer/Principal | 01/01/1998 |
| BASF Bioresearch Corp. | Corporate Officer/Principal | 01/01/1996 |
The Burroughs Wellcome Fund
 The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Corporate Officer/Principal | 01/01/1993 |
Formation de Michael Fisher
| University of Massachusetts | Undergraduate Degree |
| Worcester Polytechnic Institute | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
AutoImmune, Inc.
AutoImmune, Inc. Pharmaceuticals: MajorHealth Technology AutoImmune, Inc. develop products to treat autoimmune and other cell-mediated inflammatory conditions. Its products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects. The company was founded in September 1988 and is headquartered in Pasadena, CA. | Health Technology |
Alpha-Beta Technology, Inc.
Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Electronic Technology |
| BASF Bioresearch Corp. | |
The Burroughs Wellcome Fund
The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Miscellaneous |
Life Technologies, Inc.
 Life Technologies, Inc. BiotechnologyHealth Technology Life Technologies, Inc. provides essential technologies needed by the biotechnology and biopharmaceutical communities. The company manufactures and markets a breadth of offerings unique in the industry, used in applications of the life sciences discovery, development, and production process | Health Technology |
MedChem Products, Inc.
 MedChem Products, Inc. BiotechnologyHealth Technology Part of Becton, Dickinson & Co., MedChem Products, Inc. is a company that produces catheters and surgical products. The company is based in Woburn, MA. MedChem Products was acquired by C. R. Bard, Inc. (New Jersey), part of Becton, Dickinson & Co. from December 29, 2017 on September 28, 1995 for $101.80 million. | Health Technology |
